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DEFECTS 
J.M. Scott, D.G. Weir, A. Molloy, J. McPartlin, 1. Daly, P. Kirke, M. Conley, 
J. Lee, and J. Mills 
Introduction 
Evidence continues to confirm that periconceptional 
ingestion of folic acid can prevent neural tube defects, 
although the basis of this prevention has been unclear. 
To further elucidate the mechanism by which this 
occurs, blood samples were collected from more than 
50,000 pregnant women and the samples analyzed 
for red cell folate, plasma folate, plasma vitamin 
B12, and plasma homocysteine levels. Based on the 
results, it appears that the beneficial effect of folic 
acid is in overcoming a metabolic block in a folate-
dependent enzyme or transport process. It is likely 
that methionine synthase may be directly or indi-
rectly involved. 
The neural plate closes to form the spinal cord and 
the cranium between days 24 and 28 postconception. 
Incomplete closure of the former causes spina bifida; 
of the latter, anencephaly. The two conditions are 
called neural tube defects (NTD) [l}. Earlier evidence 
that folic acid taken periconceptionally by 
women could prevent NTDs (2-4} has recently 
been confirmed by two randomized trials using 
peri conceptional ingestion of folic acid supplements 
(5,6}. 
There are three possible ways by which folic acid 
might exert this protective effect: (1) it might treat 
folate deficiency; (2) it might overcome malabsorp-
tion; or, (3) it might overcome a metabolic block. The 
future public health response to this important devel-
opment would depend to a considerable extent on 
which one of these three mechanisms is actually in-
volved. If simple folate deficiency is involved, protec-
tion might be achieved at levels of folic acid far lower 
than the 400 lJ,g per day used in the trials. By con-
trast, if folic acid overcomes malabsorption or an im-
pairment or block in some folate-dependent enzyme 
or process, the relatively high levels of folic acid used 
in the trials may be essential to achieve protection. 
We set out to test which of the three was the 
operative alternative by collecting blood samples 
from women early in pregnancy, when their folate 
status would most accurately reflect that pertaining to 
the time of closure of the neural tube (days 24-28 
postconception). When it was subsequently ascer-
tained which women had an NTD-affected preg-
nancy, blood samples were retrieved and their plasma 
and red cell folates (RCFs) were compared with con-
trols matched for length of storage. We further inves-
tigated evidence that a metabolic block in folate 
metabolism actually existed in these women. 
Materials and Methods 
Between March 1986 and March 1990 more than 
50,000 blood samples were collected at the first book-
ing clinic from women attending the three Dublin 
Maternity Hospitals (Coombe, Rotunda, and Na-
tional Maternity). These three hospitals carry out 
most of the deliveries in the greater Dublin area, and 
the collections represented more than 70% of these, 
giving a very representative cohort. Blood was col-
lected into potassium EDTA. A sample of this whole 
blood was taken and diluted 1 in 10 into 1 % ascorbic 
acid in water for RCF analysis (7}. Plasma was sepa-
rated by centrifugation. All samples were stored at 
-20°C until analyzed. For the study, samples from 
the women who had an NTD-affected pregnancy 
(cases) were identified and retrieved. Samples were 
also identified from a randomly selected group of 
women with normal pregnancy outcomes (controls) 
taken over the same period and in the same hospitals. 
This resulted in 81 cases and 247 controls on which 
an analysis for RCF and plasma folate was carried out 
(7}. Plasma vitamin B12 levels were also estimated on 
these samples (8}. Plasma homocysteine levels were 
assayed by a modification of a previous method (9}' 
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Results 
For plasma folate, the median (range) for the cases was 
3.5/-lg/L (0.7-20.8; n = 81) and for controls was 
4.6/-lg/L (0.5-22.1; n = 247). Values for cases were 
significantly lower (p = 0.001). Comparable results 
for RCF in cases were 269/-lg/L (39-715; n = 81) and 
in controls were 338/-lg/L(80-1302; n= 247). Again, 
values for cases were significantly lower (p = 0.002). 
Of significance is that only seven cases (8.6%) had 
plasma folate levels that would be considered defi-
cient «1.5/-lg/L) (table 18-1). Similarly, consider-
ation of RCF values in the cases found only 11 
(13.6%) with deficient values «150 /-lg/L). Likewise, 
it was clear that very few cases (5 (6.1 %» had vitamin 
B12 levels in the deficient range «150 ng/L) (table 
18.2). Plasma folate levels were found to be a risk 
factor for an NTD-affected birth [l0}. Of greater 
significance was that plasma vitamin B12 levels acted 
as an independent risk factor for an affected pregnancy. 
There was also no correlation between the plasma 
folate level and the plasma vitamin BI2 level in either 
cases or controls (fig. 18-1). 
TABLE 18-1. Percentage of cases 
and controls that have "deficient folate 
status" as determined by the usual criteria 
for red cell folate and plasma folate deficiency 
Red cell folate 
(Ilg/L) 
<150 
>150 
Plasma folate 
(Ilg/L) 
<1.5 
>1.5 
Deficient and normal folate levels 
CASES: N = 81 
11 (13.6%) 
70 (86.4%) 
7 (8.6%) 
74 (91.4%) 
CONTROLS: N = 247 
7 (2.8%) 
240 (97.2%) 
10 (4.0%) 
237 (96.0%) 
TABLE 18-2. Percentage of cases and 
controls that have deficient status as 
determined at two levels of plasma vitamin BI2 
Plasma B12 
(ng/L) 
<150 
>150 
<200 
>200 
Deficient and normal plasma B12 levels 
CASES: N = 82 
5 (6.1%) 
77 (93.9%) 
14 (17.1%) 
68 (82.9%) 
CONTROLS: N = 251 
8 (3.2%) 
243 (96.8%) 
26 (10.4%) 
225 (89.6%) 
The plasma homocysteine level was compared be-
tween cases and controls. This was done by dividing 
each into deciles of plasma vitamin B12• At the lower 
vitamin BI2 levels there were significantly higher 
plasma homocysteine levels III the cases compared 
with the controls [lI}. 
DISCUSSION 
There is now conclusive evidence that periconcep-
tional supplementation of women with the vitamin 
folic acid prevents the vast majority ofNTDs (5,6}. It 
was not clear if this prophylaxis was brought about by 
treating women who are (1) deficient in folate, (2) 
overcoming an intestinal malabsorption, or whether 
(3) the higher level of folic acid intake (an extra 
400/-lg per day) overcomes some as yet unidentified 
metabolic block in folate metabolism. We deter-
mined folate status in women who went on to have an 
affected child later in their pregnancy. This was done 
by determining both their plasma folate level and 
their RCFs and matching them to randomly collected 
controls from similar women with normal pregnan-
cies collected and stored in a similar manner. In 
nearly half of the cases and controls, blood was col-
lected before 14 weeks postconception. The third 
quarter was collected between 14-20 weeks, and the 
remaining quarter at greater than 21 weeks. 
Plasma folate is considered to be a reasonable index 
of folate status. It is, however, subject to daily fluctua-
tions and changes over days or weeks if there is a 
significant alteration of folate ingestion. It would 
thus be difficult to be sure that plasma folate taken 
some ten to perhaps 20 weeks after the closure of the 
neural tube (days 24 to 28) would reflect folate status 
at that critical time. By contrast, RCF is recognized as 
a superb index of average folate status over a pro-
tracted period. This is because the folate placed in the 
red cell is done so exclusively during the period of 
the production and maturation of the red cell in the 
bone marrow. During that period the folate contents 
of all red cells is determined by the plasma folate 
levels that exist at that time. Once the red cell ma-
tures, it neither absorbs any further folate nor loses 
folate until its destruction, usually at 120 days. Thus, 
RCF reflects the average plasma folate level and the 
average status over the previous seven weeks. There-
fore, RCF is considered a very stable indication of 
folate status. 
While the cases in our study had significantly 
lower plasma and RCF levels than the controls, the 
important question with regard to the hypothesis 
being addressed concerns the number of cases that 
were likely to be folate deficient at the time of closure 
of the neural tube. While we do not have either 
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FIGURE 18-1. Regression analysis between log transformed 
plasma vitamin B12 and log transformed plasma folate in 
controls (top) and cases (bottom). indicating that folate deficiency per se is not the cause 
ofNTDs, at least not in the normal meaning of folate 
deficiency. These findings would also appear to rule 
out the contention of others [12,13J that intestinal 
malabsorption of folate is involved in the etiology of 
NTDs. Were this the case, one would expect this to 
be reflected in a large number of cases, which clearly 
they do not (table 18-1). 
plasma samples or ReF samples taken during that 
critical, one-month period into pregnancy, it seems 
reasonable that our ReF values would reflect that 
earlier status. It can be seen from the results that some 
86% of cases have ReF values in the normal range, 
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Thus, it would appear that the beneficial effect of 
folic acid is in overcoming a metabolic block in some 
folate-dependent enzyme or transport process. There 
are 16 folate-dependent enzymes. We found that, as 
with folate, almost all of the cases had plasma vitamin 
Bl2 levels in the normal range, indicating that they 
were not vitamin B12 deficient (table 18-2). However 
logistic regression analysis showed that the plasma 
vitamin B12 level was an independent risk factor for 
NTDs. We have shown experimentally that plasma 
folate and plasma vitamin B12 are not correlated either 
in cases or controls (fig. 18-1); the vitamin B12 level is 
not simply reflecting plasma folate level, which 
would make it a dependent risk factor. Methionine 
synthase is the only enzyme that is dependent for 
its activity on both folate and vitamin B12. This 
would suggest that the activity of methionine 
synthase is directly or indirectly involved in the de-
velopment of NTDs. Our finding of an abnormality 
in homocysteine metabolism in the cases compared 
with the controls supports the hypothesis that me-
thionine synthase may be directly or indirectly in-
volved [II}. The effect could be direct in that some 
NTDs might be caused by an abnormal methionine 
synthase, or indirect in that if there was an abnormal-
ity in an enzyme like 5,10 methylenetetrahydrofolate 
reductase, variations in activity of the synthase might 
determine whether a woman would become a case or 
control. 
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